|
Opening Pandora’s Pillbox: Using Modern Information Tools To Improve Drug Safety
Scott Gottlieb
How the Food and Drug Administration (FDA) responds to criticism of its drug safety process will determine whether drug safety actually improves. Propping up the Office of Drug Safety with more bureaucratic prominence or adding new requirements to the preapproval process will add to the cost of drug development and not make drugs safer. New information tools can dramatically improve postmarketing surveillance and collection of data on safety. This information could then be used to reach more definitive regulatory conclusions sooner. New incentives will be needed to entice payers and product developers to work on building a broader, more robust system for collecting data on drug safety.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Dresser and J. Frader
Off-label prescribing: a call for heightened professional and government oversight.
J. Law Med. Ethics,
September 1, 2009;
37(3):
476 - 486.
[PDF]
|
|
|
|
|
|
|
R. Dresser
Off-Label Indications for Medication Use and the Published Literature
JAMA,
September 24, 2008;
300(12):
1411 - 1411.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Platt and A. Ommaya
A Beneficial Side Effect of the Medicare Drug Benefit
N. Engl. J. Med.,
December 29, 2005;
353(26):
2742 - 2743.
[Full Text]
[PDF]
|
|
|
|
